• 1. An alternative biorefinery approach to address microalgal seasonality: blending with spent coffee grounds
  Andre Prates Pereira,Tao Dong,Eric P. Knoshaug,Nick Nagle,Ryan Spiller,Bonnie Panczak,Christopher J. Chuck,Philip T. Pienkos Sustainable Energy Fuels, 2020,4, 3400-3408
• 2. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 3. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644
• 4. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 5. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388

Introduction to 2,3-Difluoro-6-phenylmethoxybenzaldehyde (CAS No: 947279-31-4)

2,3-Difluoro-6-phenylmethoxybenzaldehyde, with the CAS number 947279-31-4, is a fluorinated aromatic aldehyde that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to a class of molecules that exhibit unique structural and electronic properties, making it a valuable scaffold for the development of novel therapeutic agents. The presence of both fluorine atoms and a phenylmethoxy group in its molecular structure imparts distinct reactivity and binding characteristics, which are highly relevant in the design of bioactive molecules.

The chemical structure of 2,3-Difluoro-6-phenylmethoxybenzaldehyde consists of a benzaldehyde core substituted with two fluorine atoms at the 2 and 3 positions, and a phenylmethoxy group at the 6 position. This arrangement creates a molecule with enhanced lipophilicity and metabolic stability, which are critical factors in drug development. The fluorine atoms, in particular, play a crucial role in modulating the pharmacokinetic properties of the compound, including its absorption, distribution, metabolism, and excretion (ADME) profiles.

In recent years, there has been growing interest in fluorinated aromatic compounds due to their ability to improve drug efficacy and bioavailability. The introduction of fluorine atoms into organic molecules can lead to increased metabolic stability, reduced susceptibility to enzymatic degradation, and enhanced binding affinity to biological targets. These properties make fluorinated compounds particularly attractive for the development of drugs that require prolonged half-lives or improved target specificity.

One of the most compelling aspects of 2,3-Difluoro-6-phenylmethoxybenzaldehyde is its potential as a building block for more complex pharmacophores. The aldehyde functionality provides a reactive site for further chemical modification, allowing chemists to explore a wide range of derivatives with tailored biological activities. For instance, this compound can be used to synthesize Schiff bases or heterocyclic compounds that exhibit antimicrobial, anti-inflammatory, or anticancer properties.

Recent studies have highlighted the importance of fluorinated aldehydes in medicinal chemistry. A notable example is the use of such compounds in the development of protease inhibitors, where the presence of fluorine atoms can enhance binding interactions with target enzymes. Additionally, fluorinated aromatic aldehydes have shown promise in the treatment of neurological disorders due to their ability to cross the blood-brain barrier more effectively than their non-fluorinated counterparts.

The synthesis of 2,3-Difluoro-6-phenylmethoxybenzaldehyde typically involves multi-step organic reactions that require careful optimization to achieve high yields and purity. Common synthetic routes include Friedel-Crafts alkylation followed by selective fluorination and methoxylation. Advanced techniques such as palladium-catalyzed cross-coupling reactions may also be employed to introduce specific functional groups with high precision.

In terms of applications, 2,3-Difluoro-6-phenylmethoxybenzaldehyde has been explored in various preclinical studies as a potential lead compound for drug discovery. Its unique structural features make it suitable for targeting multiple disease pathways simultaneously. For example, researchers have investigated its activity against enzymes involved in cancer cell proliferation and inflammation-related diseases. The compound's ability to modulate protein-protein interactions has also been studied as a strategy for developing treatments for neurodegenerative disorders.

The pharmacological profile of 2,3-Difluoro-6-phenylmethoxybenzaldehyde is further enhanced by its solubility characteristics. Unlike many traditional small-molecule drugs that suffer from poor water solubility, this compound exhibits reasonable solubility in both aqueous and organic solvents, facilitating its use in formulation development. This property is particularly important for oral and parenteral drug delivery systems.

Electrochemical studies have also provided insights into the reactivity of 2,3-Difluoro-6-phenylmethoxybenzaldehyde. The presence of electron-withdrawing fluorine atoms influences its redox potential, making it a candidate for applications in electrochemical biosensors or as an intermediate in organic electronics. These findings underscore the versatility of this compound beyond its pharmaceutical applications.

The future prospects for 2,3-Difluoro-6-phenylmethoxybenzaldehyde are promising as ongoing research continues to uncover new synthetic methodologies and biological activities. Collaborative efforts between academic institutions and pharmaceutical companies are likely to drive innovation in this area. With advancements in computational chemistry and high-throughput screening technologies, the identification of novel derivatives with enhanced therapeutic profiles is expected to accelerate.

In conclusion, 2,3-Difluoro-6-phenylmethoxybenzaldehyde(CAS No: 947279-31-4) represents a significant advancement in medicinal chemistry due to its unique structural features and potential applications. Its role as a versatile scaffold for drug development underscores its importance in addressing unmet medical needs across various therapeutic areas.

• 773873-26-0(2,3-Difluoro-6-methoxybenzoic acid)
• 504414-07-7(BENZALDEHYDE, 4-FLUORO-5-METHYL-2-(PHENYLMETHOXY)-)
• 167684-02-8(6-Ethoxy-2,3-difluorobenzaldehyde)
• 819076-06-7(Benzaldehyde, 4-[(2-fluorophenyl)methoxy]-2,6-dimethoxy-)
• 920525-53-7(Benzaldehyde, 4-fluoro-2-[(4-methoxyphenyl)methoxy]-5-methyl-)
• 851775-89-8(BENZALDEHYDE, 4-[(2-FLUOROPHENYL)METHOXY]-2-METHOXY-)
• 199388-09-5(Benzoic acid, 4-[(3-fluoro-2-formylphenoxy)methyl]-)
• 941608-36-2(2-Benzyloxy-6-Fluoro-Benzoic Acid)
• 701265-03-4(Benzaldehyde, 2-fluoro-6-(phenylmethoxy)-)
• 773876-05-4(2,3-Difluoro-6-methoxybenzoic acid methyl ester)